ArticleThe American journal of tropical medicine and hygiene2026
Decreasing the Burden of West Nile Virus Disease: The Need for More Prevention Measures.
Article in The American journal of tropical medicine and hygiene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After the introduction of West Nile virus (WNV) in 1999, the virus became endemic in the United States, causing approximately 1,300 severe neurological disease cases and 130 deaths annually. WNV is also responsible for a substantial disease burden in Canada, Europe, and countries around the Mediterranean Sea. WNV prevention currently relies on personal protective behaviors (PPBs) and mosquito control, but these measures have been inadequate to substantially reduce WNV disease cases or deaths. Additional measures are also necessary to diagnose, treat, prevent, and control WNV disease. Human WNV vaccine, anti-WNV monoclonal antibody used as preexposure prophylaxis in patients at higher risk for severe WNV disease, and more rapidly detecting WNV infection, among other measures, will be critical to help combat WNV disease morbidity and mortality. Partners in government, academia, and private industry should collaborate to ensure optimal use and availability of current and additional lifesaving measures.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.